Chemotherapy resistance arises invariably in small cell lung cancer (SCLC). In this issue of Cancer Cell, Gardner et al. find that in some SCLC, EZH2 mediates resistance via downregulation of Schlafen11 (SLFN11). Combining EZH2 inhibition with chemotherapy effectively overcomes drug resistance of xenografted SCLC, holding promise for new treatment paradigms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccell.2017.01.013 | DOI Listing |
Publication Analysis
Top Keywords
chemotherapy resistance
8
awakening "schlafen11"
4
"schlafen11" tackle
4
tackle chemotherapy
4
resistance
4
sclc
4
resistance sclc
4
sclc chemotherapy
4
resistance arises
4
arises invariably
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!